SCHEMBL2416827

SCHEMBL2416827

CC(C)(Sc1nc(CNC(=O)c2ccc(-c3ccc(Cl)cc3)cc2)cs1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.50
▸ RHOC P08134 1/20 0.48
▸ RHOA P61586 1/20 0.48
▸ PPARA Q07869 5/20 0.48
▸ MAPT P10636 2/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ POLB P06746 4/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ SLC22A12 Q96S37 2/20 0.41
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ AGTR1 P30556 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419252 0.89 NPC1 (0.43) TP53RHOCRHOAPPARAMAPT
SCHEMBL12273068 0.88 RHOC (0.48) TP53RHOCRHOAPPARAMAPT
SCHEMBL2413442 0.80 CTPS1 (0.48) TP53PPARAMAPTMEN1KMT2A
SCHEMBL2413314 0.80 POLB (0.57) TP53MAPTPOLBNPC1RAB9A
SCHEMBL2411182 0.79 PPARA (0.42) TP53PPARASLC22A12NPC1RAB9A
SCHEMBL2410536 0.78 PPARA (0.43) TP53PPARAMAPTSLC22A12LMNA
SCHEMBL2413459 0.77 TP53 (0.42) TP53PPARAMAPTSLC22A12LMNA
SCHEMBL2412511 0.77 RHOC (0.45) TP53RHOCRHOAPPARAMAPT
SCHEMBL2415234 0.76 PPARA (0.40) TP53PPARAMAPTSLC22A12NPC1
SCHEMBL12273867 0.76 TP53 (0.41) TP53PPARAMAPTSLC22A12LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US claimed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG TP53 2553/4885RHOC 4872/4885RHOA 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback